PubMed · 1991 · 73 citations · 3 references
Open access
MedicineEndocrinologyNephrologyDiabetologyKidney TransplantationTransplant ImmunologyDiabetes ManagementDiabetes MellitusImmunosuppression In Kidney TransplantationRenal DiseaseTransplant PharmacologyTransplant RejectionCyclosporine DosingDrug OnsetKidney Transplant PharmacotherapyMetabolic Complications After TransplantationMetabolic Complications Of Immunosuppression
The development of diabetes mellitus in the renal transplant population was first reported by Starzl in 1964 and was attributed to the use of steroids.1 Since then, posttransplant diabetes mellitus has been associated with the use of other immunosuppressive agents, such as cyclosporine (CyA). Because FK 506 is also thought to be diabetogenic,2 We retrospectively looked at the incidence of new onset diabetes mellitus in patients treated primarily with either FK 506 or CyA in a randomized trial of kidney transplantations done at the University of Pittsburgh from February 1990 to May 1991.
3
Experience in Renal Transplantation
Thomas E. Starzl · The American Journal of the Medical Sciences · 1965 · 371 citations
Medicine, Nephrology, Surgery +12
Kidney Transplantation Under FK 506
T. E. Starzl · JAMA · 1990 · 234 citations
Medicine, Immunology, Pharmacology +17